Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2021
Drug name
Ryaltris® (olopatadine hydrochloride / mometasone furoate monohydrate)
Glenmark Pharmaceuticals Europe Ltd
Decision date
Therapeutic area
Respiratory conditions
Therapeutic sub area
Respiratory conditions: general and other
Recommended with restrictions
In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.
Decision Detail
Following an abbreviated submission, olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) is accepted for restricted use within NHSScotland. SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis. Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment choice that combines antihistamine and glucocorticoid in a single nasal spray.